Zoetis [ZTS] vs Neurocrine [NBIX] Detailed Stock Comparison
Zoetis
NYSE
Loading...
Neurocrine
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Zoetis wins in 10 metrics, Neurocrine wins in 9 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Zoetis | Neurocrine | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.36 | 38.94 | Zoetis |
| Price-to-Book Ratio | 13.14 | 4.84 | Neurocrine |
| Debt-to-Equity Ratio | 137.01 | 18.18 | Neurocrine |
| PEG Ratio | 23.24 | 21.19 | Neurocrine |
| EV/EBITDA | 17.91 | 23.82 | Zoetis |
| Profit Margin (TTM) | 27.83% | 13.88% | Zoetis |
| Operating Margin (TTM) | 40.20% | 21.18% | Zoetis |
| EBITDA Margin (TTM) | 40.20% | 21.18% | Zoetis |
| Return on Equity | 52.77% | 13.39% | Zoetis |
| Return on Assets (TTM) | 15.37% | 8.67% | Zoetis |
| Free Cash Flow (TTM) | $2.30B | $557.20M | Zoetis |
| Dividend Yield | 1.11% | N/A | N/A |
| 1-Year Return | -16.11% | -8.35% | Neurocrine |
| Price-to-Sales Ratio (TTM) | 6.96 | 5.20 | Neurocrine |
| Enterprise Value | $70.67B | $12.57B | Zoetis |
| EV/Revenue Ratio | 7.53 | 5.01 | Neurocrine |
| Gross Profit Margin (TTM) | 73.62% | 98.36% | Neurocrine |
| Revenue per Share (TTM) | $21 | $25 | Neurocrine |
| Earnings per Share (Diluted) | $5.81 | $3.38 | Zoetis |
| Beta (Stock Volatility) | 0.88 | 0.25 | Neurocrine |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Zoetis vs Neurocrine Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Zoetis | 1.51% | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% |
| Neurocrine | 1.21% | 6.31% | 1.26% | 10.50% | 16.61% | -3.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Zoetis | -16.11% | -9.09% | -2.69% | 242.31% | 396.97% | 396.97% |
| Neurocrine | -8.35% | 24.21% | 17.50% | 203.77% | 2,152.54% | 182.11% |
Performance & Financial Health Analysis: Zoetis vs Neurocrine
| Metric | ZTS | NBIX |
|---|---|---|
| Market Information | ||
| Market Cap | $65.30B | $13.05B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 4,111,510 | 1,278,970 |
| 90 Day Avg. Volume | 3,459,870 | 982,507 |
| Last Close | $167.10 | $132.90 |
| 52 Week Range | $139.70 - $200.33 | $84.23 - $154.87 |
| % from 52W High | -16.59% | -14.19% |
| All-Time High | $249.27 (Dec 27, 2021) | $157.98 (Jul 29, 2024) |
| % from All-Time High | -32.96% | -15.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.17% |
| Quarterly Earnings Growth | 0.15% | 0.65% |
| Financial Health | ||
| Profit Margin (TTM) | 0.28% | 0.14% |
| Operating Margin (TTM) | 0.40% | 0.21% |
| Return on Equity (TTM) | 0.53% | 0.13% |
| Debt to Equity (MRQ) | 137.01 | 18.18 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $11.21 | $27.22 |
| Cash per Share (MRQ) | $3.28 | $9.84 |
| Operating Cash Flow (TTM) | $2.93B | $567.30M |
| Levered Free Cash Flow (TTM) | $2.29B | $367.04M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.11% | N/A |
| Last 12-Month Dividend | $1.86 | N/A |
Valuation & Enterprise Metrics Analysis: Zoetis vs Neurocrine
| Metric | ZTS | NBIX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.36 | 38.94 |
| Forward P/E | 23.24 | 21.19 |
| PEG Ratio | 23.24 | 21.19 |
| Price to Sales (TTM) | 6.96 | 5.20 |
| Price to Book (MRQ) | 13.14 | 4.84 |
| Market Capitalization | ||
| Market Capitalization | $65.30B | $13.05B |
| Enterprise Value | $70.67B | $12.57B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.53 | 5.01 |
| Enterprise to EBITDA | 17.91 | 23.82 |
| Risk & Other Metrics | ||
| Beta | 0.88 | 0.25 |
| Book Value per Share (MRQ) | $11.21 | $27.22 |
Financial Statements Comparison: Zoetis vs Neurocrine
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ZTS | NBIX |
|---|---|---|
| Revenue/Sales | $2.22B | $572.60M |
| Cost of Goods Sold | $622.00M | $9.20M |
| Gross Profit | $1.60B | $563.40M |
| Research & Development | $157.00M | $263.20M |
| Operating Income (EBIT) | $846.00M | $23.70M |
| EBITDA | $991.00M | $40.30M |
| Pre-Tax Income | $810.00M | $14.70M |
| Income Tax | $179.00M | $6.80M |
| Net Income (Profit) | $631.00M | $7.90M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ZTS | NBIX |
|---|---|---|
| Cash & Equivalents | $1.72B | $194.10M |
| Total Current Assets | $5.88B | $1.64B |
| Total Current Liabilities | $3.39B | $522.90M |
| Long-Term Debt | $5.40B | $447.50M |
| Total Shareholders Equity | $4.66B | $2.54B |
| Retained Earnings | $12.38B | $-5.30M |
| Property, Plant & Equipment | $6.36B | $589.20M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ZTS | NBIX |
|---|---|---|
| Operating Cash Flow | $567.00M | $21.80M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $438.00M | $54.10M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-443.00M | $-150.00M |
Short Interest & Institutional Ownership Analysis
| Metric | ZTS | NBIX |
|---|---|---|
| Shares Short | 7.85M | 2.85M |
| Short Ratio | 2.67 | 3.10 |
| Short % of Float | 0.02% | 0.04% |
| Average Daily Volume (10 Day) | 4,111,510 | 1,278,970 |
| Average Daily Volume (90 Day) | 3,459,870 | 982,507 |
| Shares Outstanding | 448.47M | 99.40M |
| Float Shares | 442.37M | 98.00M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.98% | 0.98% |
Dividend Analysis & Yield Comparison: Zoetis vs Neurocrine
| Metric | ZTS | NBIX |
|---|---|---|
| Last 12-Month Dividend | $1.86 | N/A |
| Last 12-Month Dividend Yield | 1.11% | N/A |
| 3-Year Avg Annual Dividend | $1.63 | N/A |
| 3-Year Avg Dividend Yield | 0.24% | N/A |
| 3-Year Total Dividends | $4.90 | N/A |
| Ex-Dividend Date | Apr 21, 2025 | N/A |